Transgene Biotek Ltd
NSE: BSE: 526139
₹2.69
(2.67%)
Sun, 01 Mar 2026, 00:10 am
Market Cap172.32M
PE Ratio0
Dividend0
Health Technology
Biotechnology
24.5KCompany History
1990
- Transgene Biotek Limited was incorporated as a Private Limited Company on 1st March.
- The company was subsequently converted into a Public Limited Company on 28th November.
1993
- The company commenced commercial production.
2011
- The company set up a wholly-owned subsidiary in Hong Kong named Transgene Biotek HK Ltd.
2012
- Transgene readied to launch one of its block-buster drugs - TrabiDHA (DHA) formulations.
2013
- Transgene signed a Joint Venture agreement with Atral Cipan of Portugal involving the technology transfer of Tacrolimus.
- Transgene Biotek became the worldâs first company to create and launch 50% algal DHA oil and 20% algal DHA powder.
2014
- Sri Sarang Subhash Puranik and Shyam Shankar Das were appointed as Directors of the company.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800